ribosomal protein L31 pseudogene 12Genealiases: []
Q-omics provides the consensus-scored RPL31P12 profile across patient tissues and cancer cell-line models. RPL31P12 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RPL31P12 is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, RPL31P12 RNA expression shows 5,880 significant gene co-expression associations, with the highest sampling consensus in OV. Together, these results highlight UCEC, LUSC, and OV as cancer lineages where RPL31P12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL31P12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL31P12 survival associations across molecular data types. RPL31P12 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL31P12 RNA expression–survival associations across cancer types. High RPL31P12 expression shows unfavorable associations in UCEC, ACC, UCS, STAD and KIRP, but favorable associations in THYM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for RPL31P12 RNA expression.
This table summarizes RPL31P12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL31P12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL31P12 shows lower tumor expression in LUSC, LUAD and COAD and higher tumor expression in ESCA, CHOL and PRAD. The LUSC box plot shows higher RPL31P12 RNA expression in normal versus tumor tissue (log2 FC = −0.084, t-test p = .010).
This table shows molecular features associated with RPL31P12 in patient tissues and cancer cell lines. In patient samples, RPL31P12 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
